Pre-existing anti-factor VIII immunity alters therapeutic platelet-targeted factor VIII engraftment following busulfan conditioning through cytotoxic CD8 T cells
Weiqing Jing(Versiti Blood Center of Wisconsin), Qizhen Shi(Children's Hospital of Wisconsin), Feng Xue(Chinese Academy of Medical Sciences & Peking Union Medical College), Jocelyn A. Schroeder(Medical College of Wisconsin), Christina K. Baumgartner(AbbVie (United States))
Cited by 4
Related Papers
Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies
|Journal of Clinical Investigation|2006|188
Melanoma and microbiota: Current understanding and future directions
|Cancer Cell|2023|78
Peptide-MHC Class II Complex Stability Governs CD4 T Cell Clonal Selection
|The Journal of Immunology|2009|46
Immune tolerance induced by platelet‐targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated
|Journal of Thrombosis and Haemostasis|2017|34